TECHNOLOGY SUMMARY

Despite the burden on patients and the healthcare system, a cure for diabetes has not yet been elucidated. ECMedical’s curative solution in the form of pancreatic organoids is a first of its kind approach to functional organ replacement pushing the boundaries of biotechnological innovation on four separate fronts: 1) Biomaterial science, 2) Vascular network engineering, 3) Immunocompatible cell transplantation, and 4) Pioneering the FDA approval pathway for organ replacement technologies. 1. Biomaterial Science: Originally thought to solely provide structural support to the different organs and tissues of the body, the ECM is now recognized to constitute a reservoir of information in the form of molecular and mechanical cues that contribute to the maintenance of cellular homeostasis and the promotion of optimal tissue/organ function. 2. Vascular Tissue Engineering: ECMedical’s approach to vascular tissue engineering will permit the development of adequately-sized constructs capable of producing euglycemia in humans for the first time. 3. Immunocompatible cell transplantation: ECMedical’s solution to the problem of immunorejection is manufacturing universal donor cells via genetic engineering. 4. Regulatory approval: This project is innovative from a regulatory perspective because it would pave the way and set FDA precedent for organoids.

AREA/MATURITY/AWARDS

Primary Application Area: Biotech, Pharma

Technology Development Status: Prototype

Technology Readiness Level: TRL 3

Vetted Programs/Awards: DARPA DoD STTR Phase I, $225,000, Q1 2019

SHOWCASE SUMMARY

Organization Type: Early-stage Startup (Seed)

Showcase Booth #: 9M

Website: http://www.ECMedical.net

GOVT/EXTERNAL FUNDING SOURCES

External Funding to Date: * Self-funded - $15,000
* DARPA/DoD - $225,000
* Crowd source funding - $5,000
* Philanthropic organizations - $15,000
* Financial institutional business loan - $100,000